<DOC>
	<DOCNO>NCT01741116</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety Dovitinib ( TKI258 ) patient castration resistant prostate cancer failure docetaxel-based chemotherapy . Further correlative study metabolic response use PET image change serum fibroblast growth factor 23 ( FGF23 ) conduct .</brief_summary>
	<brief_title>Dovitinib ( TKI258 ) Patients With Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>Growth factor signal important carcinogenesis progression prostate cancer , fibroblast growth factor ( FGF ) important role regard . FGF ligands ( FGF1 , -2 , -6 , -8 , -17 ) FGF receptor ( FGFR1 FGFR4 ) show significantly overexpressed prostate cancer1-5 . And , recent study demonstrate critical role FGF family member mediate signal epithelial stromal compartment , thus , promote epithelial-mesenchymal transition ( EMT ) 6,7 . Moreover , recent study show FGF-2 mediator second wave angiogenesis tumor progression men formation castration-resistant tumor . Therefore , inhibition signal via FGF axis might viable strategy treatment castration-resistant prostate cancer . TKI258 , oral multitargeted receptor tyrosine kinase ( RTK ) inhibitor know potently inhibit class III , IV , V RTKs , show biochemical 50 percent inhibitory concentration ( IC50 ) value &lt; 20 nmol/L VEGFRs ( VEGFR-1 , VEGFR-2 , VEGFR-3 ) ; platelet-derived growth factor receptor-β ( PDGFR-β ) ; fibroblast growth factor receptor 1 , 2 , 3 ( FGFR-1,2,3 ) ; fetal liver tyrosine kinase receptor 3 ( FLT-3 ) ; KIT Ret , tyrosine kinase A ( TrkA ) , csf-1 RTKs . Due unique inhibitory activity FGF pathway , TKI258 show significant activity variety tumor xenograft model athymic mouse , include acute myeloid leukemia , multiple myeloma , colon- prostate-derived models9 . Castration-resistant prostate cancer ( CRPC ) one challenge oncology practice . Although advance chemotherapy10 , new hormonal agents11 , immunotherapeutics12 , patient subgroup still limited life expectancy . Therefore , urgent need identify therapeutic target clinical development target agent treatment CRPC . For end , sorafenib test multiple phase II study earlier13-17 ; however , clinical efficacy limit . The low efficacy sorafenib might partly explain low potency inhibition RTKs . Considering nanomolar concentration range IC50 TKI258 compare micromolar concentration multi-TKIs , efficacy TKI258 evaluate CRPC patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients histologically confirm progressive metastatic androgenindependent adenocarcinoma prostate radiographic evidence disease . No two previous cytotoxic chemotherapy Castration level testosterone ( &lt; 50 ng/dl ) achieve orchiectomy gonadotropinreleasing hormone ( GnRH ) agonist Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Finished study drug chemotherapy earlier 4 week first administration study drug . Age ≥ 20 year old Patients must follow laboratory value : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 75 x 109/L Hemoglobin ( Hgb ) &gt; 8 g/dL Serum total bilirubin : ≤ 1.5 x ULN alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.0 x upper limit normal ( ULN ) without liver metastasis Serum creatinine ≤ 1.5 x ULN serum creatinine &gt; 1.5 3 x ULN 1.5 x ULN &lt; serum creatinine &lt; 3 x ULN , calculate creatinine clearance ( CrCl ) ≥ 30 mL/min use CockcroftGault equation , see formula : CrCl = [ 140age ( year ) ] x weight ( kg ) / [ 72 x serum Cr ( mg/dL ) ] ( patient female multiply 0.85 ) Patients give write informed consent obtain accord local guideline Patients eligible study must meet following criterion Patients know brain metastasis signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastases Patients another primary malignancy within 3 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , basal squamous cell carcinoma nonmelanomatous skin cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>TKI258</keyword>
	<keyword>FGF23</keyword>
</DOC>